UNIGE document Scientific Article
previous document  unige:24251  next document
add to browser collection

Polyarthrite rhumatoïde,méthotrexate et fibrose pulmonaire : quelles évidences ?

Published in Revue médicale suisse. 2010, vol. 6, no. 240, p. 547-554
Abstract Pulmonary fibrosis is an extraarticular manifestation of rheumatoid arthritis (RA), which appears between 20 to 40% of cases. MTX is an ordinary treatment used for patients with RA. It has been suggested in some studies that a link between the use of MTX and the appearance of pulmonary fibrosis exists. Furthermore, the chronic use of MTX has been associated with the development of hepatic cirrhosis. Adenosine, a key molecule in the anti-inflammatory action of MTX seems to have a pro-fibrotic effect in some experimental models, thereby suggesting a mechanism through which MTX could lead to a fibrotic process. However, in spite of these experimental models, clinical studies have not permitted to confirm the pathogenic role of MTX in pulmonary fibrosis.
Keywords Adenosine/adverse effects/metabolismAnimalsArthritis, Rheumatoid/complications/drug therapy/pathologyHumansLiver Cirrhosis/chemically inducedMethotrexate/adverse effects/therapeutic usePulmonary Fibrosis/chemically induced/etiologySmoking/adverse effects
PMID: 20408459
Full text
Article (Published version) (684 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research groups Mécanisme de l'inflammation articulaire (44)
Acquisition de l'expertise médicale (662)
(ISO format)
SCHALLER, Dorian, NENDAZ, Mathieu, GABAY, Cem. Polyarthrite rhumatoïde,méthotrexate et fibrose pulmonaire : quelles évidences ?. In: Revue médicale suisse, 2010, vol. 6, n° 240, p. 547-554. https://archive-ouverte.unige.ch/unige:24251

374 hits

0 download


Deposited on : 2012-11-30

Export document
Format :
Citation style :